RedHill Biopharma (RDHL) AI Stock Analysis

• Market Cap: $6.82M
• Dividend Yield: N/A
• Average Volume (3M): 1.98M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.28
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 35
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -2.32
• Shares Outstanding: 5,092,326
• 10 Day Avg. Volume: 104,605
• 30 Day Avg. Volume: 1,981,143
• PEG Ratio: 0.02
• Price to Book (P/B): -3.27
• Price to Sales (P/S): 1.90
• P/FCF Ratio: -1.63
• Enterprise Value/Market Cap: 0.10
• Enterprise Value/Revenue: 0.07
• Enterprise Value/Gross Profit: 0.11
• Enterprise Value/Ebitda: -0.09
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 47 Neutral
• Price Target: $1.50 ▲(25.00% Upside)

Score is held down primarily by weak financial performance (ongoing losses, negative equity, and negative operating/free cash flow). Technicals provide a partial offset with improving short-term trend and momentum, but longer-term trend and MACD remain unsupportive. Valuation impact is neutral due to missing P/E and dividend yield.

Positive Factors

RHB-102 development via FDA 505(b)(2) for GLP-1 GI side effects

Pursuing RHB-102 under 505(b)(2) targets GI side effects of GLP-1/GIP therapies, a structural market need. A successful approval could reduce GLP-1 discontinuation, broaden commercial partners, and provide faster, lower‑risk regulatory path and sustainable revenue streams over the medium term.

Opaganib shows in vivo efficacy as oncology add-on

Demonstrated preclinical ability to resensitize venetoclax‑resistant CLL positions opaganib as a durable oncology add‑on opportunity. Coupled with existing safety data and ongoing phase 2 work, this expands the pipeline's commercial and partnership appeal across resistance-driven oncology niches.

Talicia joint venture with Cumberland boosts commercialization resources

The Talicia JV shifts commercialization risk and brings partner capital and U.S. co‑commercialization capabilities. This structural change can improve market execution, revenue share predictability and regulatory/listing compliance while allowing RedHill to reallocate resources to other pipeline priorities.

Negative Factors

Negative equity and prior high leverage

Persistent negative equity and historically high leverage constrain financial flexibility, raise refinancing and covenant risk, and limit capacity to invest in launches or trials. Such structural balance‑sheet weakness increases vulnerability to adverse outcomes and raises long‑term financing costs.

Ongoing negative operating and free cash flows

Chronic negative operating and free cash flow mean RedHill must repeatedly access external capital to fund operations and trials. This structural cash deficit constrains organic growth, forces dilution or debt reliance, and limits the company's ability to self‑fund commercialization or larger clinical programs.

Reliance on dilutive financing facilities

Dependence on standby equity facilities and ATM offerings signals a structural funding gap. While providing liquidity, these mechanisms are dilutive and can recur, reducing existing shareholders' stakes and potentially undermining long‑term capital stability if operating cash generation doesn't improve.

RedHill Biopharma Business Overview & Revenue Model

Company Description

RedHill Biopharma Ltd. is a specialty biopharmaceutical company focused on the development and commercialization of innovative therapies for gastrointestinal diseases and cancer. The company operates primarily in the biopharmaceutical sector, with a strong emphasis on creating oral drug formulations that address unmet medical needs. RedHill's core products include therapies targeting conditions such as peptic ulcers, inflammatory bowel disease, and other gastrointestinal disorders, as well as oncology treatments.

How the Company Makes Money

RedHill Biopharma generates revenue through a combination of product sales, licensing agreements, and partnerships. The company's key revenue streams come from the commercialization of its proprietary drug products, which are sold to healthcare providers and patients. In addition, RedHill enters into strategic partnerships and licensing agreements with other pharmaceutical companies to develop and market its therapies, often receiving upfront payments, milestone payments, and royalties on future sales. These collaborations not only provide immediate financial support but also enhance the company's market reach and product pipeline. Furthermore, RedHill may benefit from government grants and funding for clinical trials that support its research and development efforts.

RedHill Biopharma Financial Statement Overview

Summary

RedHill Biopharma is facing significant financial challenges, with negative net profit margins, high leverage, and persistent negative cash flows. Despite minor improvements in some metrics, the company remains in a precarious financial position.

Income Statement

RedHill Biopharma's income statement reveals a challenging financial position with negative net profit margins and EBIT margins over the periods analyzed. Although there is a slight improvement in gross profit margin in the TTM, the company continues to face significant losses. Revenue growth is inconsistent, with a recent positive trend in TTM but overall declining from previous years.

Balance Sheet

The balance sheet shows a concerning financial structure with negative stockholders' equity and high leverage ratios in previous years. The debt-to-equity ratio has improved in the TTM, but the company still faces significant financial instability. Return on equity is negative, indicating inefficiencies in generating returns from shareholders' investments.

Cash Flow

Cash flow analysis indicates persistent negative operating and free cash flows, though there is a slight improvement in free cash flow growth in the TTM. The company's ability to cover net income with operating cash flow is weak, reflecting ongoing liquidity challenges.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	9.55M	8.04M	6.53M	61.80M	85.76M	64.36M
Gross Profit	6.16M	4.85M	3.07M	28.46M	36.35M	27.47M
EBITDA	-7.91M	-7.59M	26.27M	-22.18M	-63.03M	-54.98M
Net Income	-9.31M	-8.27M	23.92M	-71.67M	-97.74M	-76.17M
Balance Sheet
Total Assets	18.38M	18.04M	23.05M	158.87M	181.19M	180.24M
Cash, Cash Equivalents and Short-Term Investments	2.87M	4.62M	6.36M	19.98M	38.00M	29.79M
Total Debt	214.00K	356.00K	1.17M	122.69M	87.81M	86.90M
Total Liabilities	22.79M	22.73M	20.98M	207.27M	172.31M	166.38M
Stockholders Equity	-4.41M	-4.68M	2.07M	-48.40M	8.88M	13.86M
Cash Flow
Free Cash Flow	-8.21M	-9.38M	-35.83M	-29.38M	-65.16M	-102.35M
Operating Cash Flow	-8.20M	-9.37M	-35.82M	-29.18M	-65.05M	-48.58M
Investing Cash Flow	-12.00K	-9.00K	3.99K	8.30M	-8.14M	-35.65M
Financing Cash Flow	3.78M	8.42M	21.38M	11.45M	73.46M	84.37M

RedHill Biopharma Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.20
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RDHL, the sentiment is Positive. The current price of 1.2 is above the 20-day moving average (MA) of 1.18, above the 50-day MA of 1.17, and below the 200-day MA of 1.68, indicating a neutral trend. The MACD of 0.02 indicates Negative momentum. The RSI at 58.81 is Neutral, neither overbought nor oversold. The STOCH value of 78.79 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for RDHL.

RedHill Biopharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
UPC	51 Neutral	$2.38M	―	2.66%	―	-27.81%	―
SNOA	50 Neutral	$6.43M	-1.72	-76.14%	―	25.02%	55.11%
RDHL	47 Neutral	$6.82M	―	―	―	―	―
PRFX	43 Neutral	$3.33M	―	―	―	―	―
CPHI	42 Neutral	$6.80M	-1.31	-42.47%	―	-26.92%	69.90%
SHPH	32 Underperform	$2.89M	-0.08	-9999.00%	―	―	79.31%

RedHill Biopharma Corporate Events

RedHill Biopharma Advances RHB-102 in GI Indications and GLP-1 Therapy Support

On January 5, 2026, RedHill Biopharma announced further development progress for its proprietary once-daily extended-release ondansetron formulation RHB-102 (Bekinda) across multiple gastrointestinal indications, including a planned Phase 2 proof-of-concept study targeting gastrointestinal side effects associated with GLP-1/GIP receptor agonist therapies used for diabetes and weight loss. Supported by positive U.S. Phase 3 data in gastroenteritis/gastritis, Phase 2 data in IBS-D, a favorable pharmacokinetic study in oncology support, and decades of ondansetron use, RedHill is pursuing U.S. FDA approval of RHB-102 under the 505(b)(2) pathway for oncology support (with potential expansion to post-operative nausea and vomiting) and positioning the drug as a once-daily oral option that could reduce GI-driven discontinuation of GLP-1 treatments, potentially enhancing its partnership appeal and strengthening the company’s presence in the fast-growing GI and metabolic therapy support markets.

The most recent analyst rating on (RDHL) stock is a Sell with a $1.00 price target. To see the full list of analyst forecasts on RedHill Biopharma stock, see the RDHL Stock Forecast page.

RedHill Biopharma Files Pro Forma Financials After Talicia Joint Venture Deal With Cumberland

On October 17, 2025, RedHill Biopharma completed a strategic transaction with Cumberland Pharmaceuticals involving Talicia®, its proprietary drug, by selling a 30% equity stake in newly formed Talicia Holdings Inc. (THI), which holds global rights to Talicia and manages its worldwide commercialization. Cumberland agreed to invest $4 million in two tranches in exchange for joint control of THI, leaving RedHill with a 70% stake but shared decision-making authority, leading RedHill to deconsolidate THI and treat its retained interest as an equity-method joint venture under IFRS; the company has now filed unaudited pro forma condensed consolidated financial information to illustrate how this loss of control, classification of Talicia operations as discontinued, and shift to joint venture accounting would have affected its historical results, signaling a structurally different financial profile for RedHill’s future reporting and Talicia-related earnings and risks.

The most recent analyst rating on (RDHL) stock is a Sell with a $1.00 price target. To see the full list of analyst forecasts on RedHill Biopharma stock, see the RDHL Stock Forecast page.

RedHill Biopharma Secures Up to $25 Million Standby Equity Facility with YA II PN

On December 19, 2025, RedHill Biopharma entered into a Standby Equity Purchase Agreement with YA II PN, Ltd., giving the company, over a 36‑month period from that date, the discretionary right to sell up to $25 million of its ADSs to the investor, subject to trading‑volume, pricing and ownership caps, including a 9.99% beneficial ownership limit. As part of the initial funding step under this structure, RedHill on the same date issued 386,593 ADSs and a pre‑funded warrant for 590,446 ADSs for gross proceeds of $1 million, agreed to pay a 2% commitment fee partly in ADSs (including 122,130 ADSs already issued), and committed to registering all related ADS resales with the SEC, a move that provides a flexible but potentially dilutive equity financing mechanism to support the company’s capital needs.

The most recent analyst rating on (RDHL) stock is a Sell with a $1.00 price target. To see the full list of analyst forecasts on RedHill Biopharma stock, see the RDHL Stock Forecast page.

RedHill Biopharma’s Opaganib Shows Promise in Combating CLL Resistance

On December 15, 2025, RedHill Biopharma announced positive in vivo results for opaganib, showing its potential to reduce Chronic Lymphocytic Leukemia (CLL) cells by 50% when combined with venetoclax, a key CLL therapy. This development highlights opaganib’s potential as an add-on therapy to overcome venetoclax resistance, which is a significant therapeutic challenge in CLL treatment. The findings are part of ongoing research, including a Phase 2 study of opaganib with darolutamide in advanced prostate cancer, and may enhance RedHill’s position in the oncology market.

The most recent analyst rating on (RDHL) stock is a Sell with a $1.00 price target. To see the full list of analyst forecasts on RedHill Biopharma stock, see the RDHL Stock Forecast page.

RedHill Biopharma Regains Nasdaq Compliance

RedHill Biopharma announced on December 1, 2025, that it successfully regained compliance with Nasdaq’s stockholders’ equity requirement as of November 26, 2025. This achievement supports RedHill’s strategic initiatives for 2025, including its partnership with Cumberland Pharmaceuticals and a focus on operational efficiency, potentially strengthening its market position and stakeholder confidence.

The most recent analyst rating on (RDHL) stock is a Sell with a $1.00 price target. To see the full list of analyst forecasts on RedHill Biopharma stock, see the RDHL Stock Forecast page.

RedHill Biopharma Expands Offering of American Depositary Shares

On November 26, 2025, RedHill Biopharma Ltd. announced an increase in the maximum aggregate offering amount of its American Depositary Shares under an At The Market Offering Agreement with H.C. Wainwright & Co., LLC. This strategic move is expected to enhance the company’s financial flexibility and support its ongoing operations and growth initiatives in the competitive biopharmaceutical industry.

The most recent analyst rating on (RDHL) stock is a Sell with a $1.00 price target. To see the full list of analyst forecasts on RedHill Biopharma stock, see the RDHL Stock Forecast page.

RedHill Biopharma Secures $10.5 Million Judgment Win

RedHill Biopharma announced that the New York Supreme Court’s judgment in favor of the company against Kukbo Co. Ltd is now final and enforceable, with no further appeals possible. The court awarded RedHill over $10.5 million, including $8.6 million in the main judgment and $1.9 million for legal fees and expenses, with interest continuing to accrue. Additionally, RedHill secured a Korean court attachment to prevent Kukbo from disposing of assets before judgment enforcement, potentially strengthening RedHill’s financial position and market confidence.

The most recent analyst rating on (RDHL) stock is a Sell with a $1.50 price target. To see the full list of analyst forecasts on RedHill Biopharma stock, see the RDHL Stock Forecast page.

RedHill Biopharma Appeals Nasdaq Delisting Notice After Equity Boost

On October 16, 2025, RedHill Biopharma received a Nasdaq Staff Determination notification for not meeting the minimum stockholders’ equity requirements for continued listing. Following a transaction with Cumberland Pharmaceuticals, RedHill believes it now meets the equity requirement and plans to appeal the determination. The company remains listed on the Nasdaq Capital Market pending a hearing, but there is no guarantee of a favorable outcome or extension.

The most recent analyst rating on (RDHL) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on RedHill Biopharma stock, see the RDHL Stock Forecast page.

RedHill Biopharma Amends Purchase Agreement with Alumni Capital

On October 20, 2025, RedHill Biopharma amended its Any Market Purchase Agreement with Alumni Capital LP, increasing the ownership limit for Forward Purchase Notices from 4.99% to 9.99%. This amendment allows RedHill greater flexibility in capital raising through the sale of American Depositary Shares, potentially impacting its financial strategy and market positioning.

The most recent analyst rating on (RDHL) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on RedHill Biopharma stock, see the RDHL Stock Forecast page.

RedHill Biopharma Secures $4 Million Investment and U.S. Partnership for Talicia

On October 17, 2025, RedHill Biopharma announced a strategic partnership with Cumberland Pharmaceuticals, involving a $4 million investment for a 30% stake in Talicia Holdings, a subsidiary managing the global rights to Talicia®. This partnership includes a five-year co-commercialization agreement in the U.S., with both companies sharing net revenues and operational responsibilities. The collaboration aims to boost Talicia’s market presence and financial performance, reinforcing RedHill’s financial position and compliance with Nasdaq listing requirements.

The most recent analyst rating on (RDHL) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on RedHill Biopharma stock, see the RDHL Stock Forecast page.

RedHill Biopharma Secures $1.8 Million Middle East Deal for Talicia

On October 6, 2025, RedHill Biopharma announced a new licensing agreement for Talicia in the Middle East, potentially worth $1.8 million plus sales royalties. This deal includes $500,000 in guaranteed payments and aims to expand Talicia’s market presence in regions with high H. pylori prevalence, enhancing RedHill’s market positioning and addressing significant medical needs.

The most recent analyst rating on (RDHL) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on RedHill Biopharma stock, see the RDHL Stock Forecast page.